| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Oral Sessions
Day 3, June 24（Tue.） 11:25-11:55
Room A (Maesato West)
- 3A-O1-1125
Metabolomics-Based Approaches to Drive the Development of Optimal Biotherapeutics Production Processes and the Unravelling of Disease Mechanisms
(1A*STAR BTI, 2A*STAR IMCB, 3A*STAR GIS, 4Duke-NUS, 5SNEC, 6SERI, 7Ozaki Eye Hospital, 8YLL School of Medicine, NUS, 9Dept. of Biological Sciences, NUS)
oYing Swan Ho1, Yin Ying Ho1, Annie Soh1, Shi Ya Mak1, Shuwen Chen1, Esther Peh1, Yu Hui Kang1, Boon Min Poh2, Boon Seng Soh2,9, Gamal Ahmed Elfar2, Chit Fang Cheok2,8, Sai Kiang Lim2, Meiyappan Lakshmanan1, Zhenxun Wang3,4,6, Chiea Chuen Khor3,6,8, Zach Pang1, Say Kong Ng1, Andy Tan1, Xuezhi Bi1,4, Tin Aung5,6,8, Mineo Ozaki6,7, Andre Choo1
Metabolomics is often described as the “-omics" science that most closely reflects the functional state of a biological system. such as cells and higher organisms. As such, metabolomic data often provide critical insights into mechanisms behind key physiological processes and how they can be altered. This talk will detail key examples of how metabolomics characterization can be leveraged upon to improve bioprocess development for the production of antibody drugs, and to decipher important mechanisms in the study of different diseases. Firstly, metabolomics-based approaches, used in combination with AI and mechanistic modelling techniques, are gaining interest in the biomanufacturing industry, as an alternative to traditional design-of-experiments workflows for optimizing the production of biologics drugs. This combined approach enables the rational, knowledge-driven design of culture media that maximises antibody production yield and quality with improved speed and efficiency. In addition, I will describe how untargeted metabolomics has guided identification of key mechanisms of action behind (i) the cardioprotective effects of mesenchymal stem cell-derived extracellular vesicles, (ii) p53-mediated protection of the replicating genome highly relevant to various cancers and how targeted metabolite profiling can be applied to a functional genomics study to determine the deleterious effects of rare genetic variants associated with glaucoma.